Abbott Laboratories (ABT)

ABT on New York Consolidated

43.59USD
19 Sep 2014
Price Change (% chg)

$-0.10 (-0.23%)
Prev Close
$43.69
Open
$43.96
Day's High
$44.20
Day's Low
$43.56
Volume
6,139,284
Avg. Vol
4,712,613
52-wk High
$44.20
52-wk Low
$32.75

ABT

Chart for ABT

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $65,546.24
Shares Outstanding (Mil.): 1,503.70
Dividend: 0.22
Yield (%): 2.02

Financials

  ABT Industry Sector
P/E (TTM): 31.32 32.84 33.70
EPS (TTM): 1.39 -- --
ROI: 6.82 18.11 17.35
ROE: 9.41 18.82 18.21
Search Stocks

Abbott dissolving stent has lower angina rate vs metal stent: study

- Abbott's Absorb dissolving heart stent proved as safe and effective one year after being placed in a diseased artery as the company's market-leading Xience drug coated metal stent with a significantly lower rate of chest pain, according to data presented at a medical meeting on Sunday.

14 Sep 2014

Abbott dissolving stent has lower angina rate vs metal stent -study

Sept 14 - Abbott's Absorb dissolving heart stent proved as safe and effective one year after being placed in a diseased artery as the company's market-leading Xience drug coated metal stent with a significantly lower rate of chest pain, according to data presented at a medical meeting on Sunday.

14 Sep 2014

Fitch Maintains CFR's IDRs on Rating Watch Positive

(The following statement was released by the rating agency) CHICAGO, August 29 (Fitch) Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release. KEY RATING DRIVERS Rating Watch Positive Fitch initially placed the co

29 Aug 2014

Mylan presses on with tax-inversion Abbott deal

- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories , Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

07 Aug 2014

UPDATE 2-Mylan presses on with tax-inversion Abbott deal

* CEO: Tax-inversion deals do not stop companies paying US taxes

07 Aug 2014

Abbott beats profit estimate, infant formulas rebound

- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

16 Jul 2014

BRIEF-Abbott CEO says growth for nutritional products, pharmaceuticals "getting back on track"

July 16 - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals

16 Jul 2014

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

Sanofi held talks with Abbott, Mylan on mature drugs -document

PARIS, July 16 - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $107.99 +0.64
Pfizer Inc. (PFE.N) $30.40 -0.18
Novartis AG (NOVN.VX) CHF88.30 -0.15
Merck & Co., Inc. (MRK.N) $60.49 +0.18
Sanofi SA (SASY.PA) €88.76 +0.30
AstraZeneca plc (AZN.L) 4,578.50p +42.00
GlaxoSmithKline plc (GSK.L) 1,449.00p +12.50
Eli Lilly and Co (LLY.N) $66.53 -0.06
Amgen, Inc. (AMGN.OQ) $144.01 +1.99
Medtronic, Inc. (MDT.N) $66.22 -0.31

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks